Home Add to Favorite Contact Submit  
           29 March, 2024


    
Category:  Press » Health & Fitness

 

DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease

Popularity:
         Views: 1803
2008-04-16 05:15:26     
Anthera Pharmaceuticals, Inc.

Anthera Pharmaceuticals, Inc., a privately held biopharmaceutical company developing anti-inflammatory drugs, announced today that after completing its review of safety and efficacy data currently available, an independent Data Safety Monitoring Board (DSMB) has recommended that Anthera's Phase II clinical trial, known as the IMPACTS (Investigation of the Modulation of Phospholipase in Acute ChesT Syndrome) Study can continue under the current protocol, without change.

IMPACTS is a Phase II multi-center clinical trial evaluating the safety and effectiveness of intravenous A-001 (varespladib sodium) in preventing the development of acute chest syndrome in hospitalized sickle cell disease patients. Enrolled patients are at-risk for acute chest syndrome based on the combination of pain (vaso-occlusive crisis), fever, and elevated serum level of the enzyme (secretory phospholipase).

"We are pleased with the DSMB's response and look forward to continuing the A-001 trial under our original protocol," said Dr. James E. Pennington, M.D., Executive Vice President and Chief Medical Officer of Anthera Pharmaceuticals, Inc. "Treatment options are limited for this important patient population and we believe a drug that provides an opportunity for early intervention would help address a significant unmet medical need."

"Today's announcement marks another exciting milestone for Anthera," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "Over the past few months, we've also made significant progress in our A-002 program for cardiovascular disease. In February, we completed our end of Phase II meeting with the FDA. In early April, we completed a pre-submission meeting with European Medicines Agency (EMEA). Presently, we are preparing to submit our registration protocols to FDA as part of the Special Protocol Assessment process."

About A-001

A-001 is a potent inhibitor of secretory phospholipase A2(sPLA2) activity, including groups IIA, V, and X. The U.S. Food and Drug Administration granted A-001 orphan drug status for the prevention of acute chest syndrome in patients with sickle cell disease in December 2007.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co., Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family - a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes, prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel, upstream steps in the inflammation cascade and have the potential to address a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com.

MEDIA CONTACT:

Anne Bowdidge (650) 218-6900

Specialized in: Anthera - Anthera Pharmaceuticals - A-001 - A-002 - Pharmaceutical - Biopharmaceutical - Antibiotic - Antibacterial - Clinical - Anti Infective - Acute Chest Syndrome - Ali - Ards - Asthma - Atherosclerosis - Psoriasis
URL: http://www.anthera.com
Print press release      Bookmark this page
Related Press releases 
ehnote Ushers in a New Era of Ophthalmology Practice Management with Groundbreaking EMR Software (Popularity: ): ehnote, a pioneer in ophthalmology-specific electronic medical record (EMR) software, unveils the latest advancements to its comprehensive solution, empowering eye care professionals to streamline operations, elevate patient care, and achieve unprecedented levels of efficiency.ehnote’s innovative EMR software is meticulously crafted to address the unique challenges faced by ophthalmology practices. Its robust suite of features empowers practitioners to optimize patient flow, enhance clinical decision-making, and simplify administrative tasks with unparalleled ease. ...
Bethesda MD In-Home Care Agency Educates Readers On Mental Exercises (Popularity: ): Rockville, Maryland ( press.abc-directory.com ) January 22, 2019 - Comfort Home Care, a Bethesda Maryland in-home care agency, released a guide for people with elderly loved ones outlining mental exercises for strengthening memory and cognition. The Maryland in-home care agency recommends that family members help elderly loved ones incorporate these exercises into their regular routines to promote better mental health.As our loved ones age, their mental abilities often decline. Reduced ...
What are Former NFL Players Doing for a Healthier Mind, Body and Soul? Dr. Moalemi of Empire Physical Medicine & Pain Management Joins the Team (Popularity: ): Mount Laurel, NJ - May 31, 2016 -- The NFL Alumni's mission is to serve, assist and inform members to enrich their post-NFL lives. The NFL Alumni care for kids and care for their own, enabling the members to connect with each other and contribute to the community through charitable programs.NFL players endure several injuries during their tenure. Over time they develop bodily aches and pains. The Optimal Wellness Challenge ...
Stay Fit & Healthy Launches New Website for Fitness Products & Services in San Jose (Popularity: ): San Jose, California- April 22, 2016- Stay Fit & Healthy, fitness expert in San Jose, California and provider of high performance fitness products in San Jose is thrilled to announce the launch of its completely new website at stayfitandhealthymelaleuca.com.The revitalized new website welcomes visitors and everyone looking for high quality and reliable fitness products including vitamins, muscle shakes, weight management products and energy drinks in San Jose and surrounding areas. ...
Caring Hands Matter Launches New Blog on Website (Popularity: ): Fairfax City, Virginia ( press.abc-directory.com ) February 12, 2016 - Fairfax home care agency, Caring Hands Matter is pleased to announce the launch of the new blog section on its organizational website. Blogs are a great way to help caregivers of elderly loved ones, individuals suffering from illness and individuals who require special needs to become more informed about their circumstances while feeling connected to the caregiving community at large. ...


Related Business 
Joint Center for Sickle Cell and Thalassemic Disorders (Popularity: ): Gives an evaluation of the causes and treatments of sickle cell disease as well as current research. Information is available both for lay persons as well as health care providers.
Beyond Sickle Cell (Popularity: ): The Final Race is a work of fiction based on science and historical facts that explores the complex interconnections between sickle cell disease, race and racism, malaria and climate change.
Sickle Cell Disease Review (Popularity: ): Promotes and disseminates research into the scientific, clinical and social aspects of this disorder. Literature review, bibliography, and general information on the disease.
Unit for the Social Study of Thalassaemia and Sickle Cell (Popularity: ): A UK based social studies site for thalassaemia and sickle cell, including bibliography, quiz, and links to other major sites.
ICAgen, Inc. (Popularity: ): Discovers and develops pharmaceutical products to treat medical conditions such as atrial fibrillation, urinary incontinence, central nervous system disorders, and sickle cell disease.
Treatment for Chronic Obstructive Pulmonary Disease (Popularity: ): Learn about a nebulized LABA that can help treat your patients COPD. Learn about this treatment option & get the full prescribing information here. PERFOROMIST Inhalation Solution should not be used for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. PERFOROMIST Inhalation Solution should not be initiated in patients with acutely deteriorating COPD, which may be a life-threatening condition.
American College of Chest Physicians (Popularity: ): It's the chest physician, the cardiac specialist, or the oncologist, that breaks the prognosis to the family. This website goes to the response of the medical community to preventable disease and death.
MaxAppeal (Popularity: ): A British charity that supports children, families and the medical community concerning DiGeorge syndrome, also known as velo-cardial facial syndrome (VCFS) and 22q11 syndrome. Find events, news, info sheets, and a newsletter.
Archemix Corp. (Popularity: ): Company developing therapeutics of aptamers, for the prevention and treatment of chronic and acute disease. Includes overview of technology and commercial potential, careers and contacts in Cambridge, Massachusetts.
Discovery Laboratories Inc. (Popularity: ): Develops and commercializes surfactant formulations for neonatal care, treatment of acute respiratory distress syndrome and lung injury. Information for patients, investors and careers in Doylestown, Pennsylvania. (Nasdaq: DSCO)